MedDataX Logo

Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines

NCT ID: NCT01391312

Last Updated: 2012-09-25

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-30

Study Completion Date

2011-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This was a pilot study to observe patient satisfaction with BOTOX® Cosmetic treatment in glabellar rhytides (frown lines) using a new treatment satisfaction measure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glabellar Frown Lines

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

botulinum toxin Type A

Botulinum toxin Type A 20U (total dose) injected into the glabellar region on Day 0.

Group Type ACTIVE_COMPARATOR

botulinum toxin Type A

Intervention Type BIOLOGICAL

botulinum toxin Type A 20U (total dose) injected into the glabellar region on Day 0.

placebo (Normal Saline)

Normal Saline (placebo) injected into the glabellar region on Day 0.

Group Type PLACEBO_COMPARATOR

normal saline (placebo)

Intervention Type DRUG

Normal saline (placebo) injected into the glabellar region on Day 0.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

botulinum toxin Type A

botulinum toxin Type A 20U (total dose) injected into the glabellar region on Day 0.

Intervention Type BIOLOGICAL

normal saline (placebo)

Normal saline (placebo) injected into the glabellar region on Day 0.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BOTOX® Cosmetic, Vistabel®, Vistabax®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Moderate to severe glabellar wrinkles (frown lines)

Exclusion Criteria

* Previous treatment with botulinum toxin therapy of any serotype
* Facial non-ablative resurfacing laser or light treatment, microdermabrasion, or superficial peels within 3 months
* Any facial cosmetic procedure with medium depth to deep facial chemical peels (e.g., trichloroacetic acid and phenol), mid-facial or periorbital laser skin resurfacing or permanent make-up within 6 months
* Mid-facial or periorbital treatment with non-permanent soft tissue fillers
* Subjects planning a facial cosmetic procedure or visible scars
* Previous cosmetic surgery to the upper face(e.g., prior periorbital surgery, facial lift, brow lift, eyelid lift or eyebrow surgery)
* Diagnoses of Myasthenia Gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis
* History of facial nerve palsy
* A planned extended absence during the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Allergan

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Director

Role: STUDY_DIRECTOR

Allergan

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

East Chicago, Illinois, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GMA-BTXC-11-001

Identifier Type: -

Identifier Source: org_study_id